TII
21.4.2021 14:47:13 CEST | Business Wire | Press release
Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), today announced that its Secure Systems Research Centre (SSRC) has partnered with Khalifa University, Georgia Institute of Technology, Tampere University and University of Applied Sciences and Arts of Southern Switzerland (SUPSI). Secure Systems Research Centre also recently announced that it had partnered with Purdue University.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210421005624/en/
The announcement of these collaborations is the latest in a series of announcements by Technology Innovation Institute since the first Advanced Technology Research Council board meeting in August 2020. Secure Systems Research Centre is one of the initial seven dedicated research centres at Technology Innovation Institute. The strategic partnerships will advance breakthroughs in the field of secure systems and its sub-disciplines across crucial projects.
The partnership with the UAE’s prestigious Khalifa University spans four major projects, the first of which explores opportunities to use machine learning for exfiltration detection on android smartphones. The second project involves the development of solutions in secure communications for power-constrained wireless mesh networks while the third investigates physical wireless security and routing protocols on drone communications. Finally, the last project looks at physical layer security for diverse unmanned aerial vehicle (UAV)-ground wireless networks. This project seeks to evaluate the vulnerabilities of these networks and propose efficient solutions to mitigate system weakness.
The partnership with Georgia Institute of Technology in the United States encompasses a project that will devise a theory for constructing attack-resilient software that can address real-time constraints in cyber-physical and autonomous systems (CPAS). The research team will demonstrate techniques that enhance the security of CPAS software and platforms, with a focus on drones. The cooperation with Tampere University in Finland comprises of a project related to critical infrastructure security. This project will uncover methods to reduce an attacker’s ability to infiltrate, steal and manipulate data in critical infrastructure. This research has prominent use-cases in areas such as drone deployment, emergency services, infrastructure on demand, and smart city data processing.
The partnership with Switzerland’s SUPSI will explore AI-based secure autonomous navigation on Nano-UAVs, focusing on security, autonomy, and resilience. The team aims to enable secure communication and computation onboard resource-constrained (i.e., computation, memory, power, and payload) cyber-physical systems (CPSs) by leveraging machine learning, deep learning, and advanced artificial intelligence techniques.
Speaking on the partnership announcements, Dr Shreekant (Ticky) Thakkar, Chief Researcher at Secure Systems Research Centre leading the Secure Autonomous Computing work, said: “Our world is more connected – and more vulnerable to cyberattacks. Smart cities, transportation and other critical infrastructure, require the highest levels of defence against these attacks. The partnerships and crucial projects that we have announced with prestigious global institutions will no doubt have far-reaching advancements in secure and resilient autonomous system solutions that encompass platforms, systems software, communications, applications, and data integrity.”
In March 2021, Technology Innovation Institute announced that Secure Systems Research Centre has partnered with Purdue University, a world-renowned US-based public research university, to collaborate on a three-year sophisticated cybersecurity project to ensure unmanned aerial vehicles can be used safely and efficiently in urban operations.
For more information about Technology Innovation Institute (TII) please visit www.tii.ae
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005624/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom